REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in...
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in...
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in...
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic...
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic...
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic...
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable,...
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable,...
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable,...
LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterallyLONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon...
LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterallyLONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon...
LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterallyLONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon...
BOCA RATON, Fla., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
BOCA RATON, Fla., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
BOCA RATON, Fla., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of...
LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of...